Publication: Efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors
No Thumbnail Available
Date
2014-07-01
Authors
Kanat, Özkan
Ölmez, Ömer Fatih
Canhoroz, Mustafa
Avcı, Nilüfer
Hartavi, Mustafa
Seyhan, Serdar
Ayyıldız, Aylin
Authors
Çubukcu, Sinem
Kanat, Özkan
Çubukcu, Erdem
Ölmez, Ömer Fatih
Canhoroz, Mustafa
Avcı, Nilüfer
Hartavi, Mustafa
Deligönül, Adem
Seyhan, Serdar
Ayyıldız, Aylin
Journal Title
Journal ISSN
Volume Title
Publisher
Derman Medical Publ
Abstract
Aim: In this study, the efficacy of sunitinib in patients with imatinib-resistant gastrointestinal stromal tumors (GISTs) was investigated. Material and Method: A total of 11 imatinib-resistant GIST patients who have sufficient information about their medical treatment and outcome were retrospectively analyzed. Results: Partial response was observed in only two patients, and five patients achieved stable disease. Progression free survival and overall time was 8.8 months and 12 months, respectively. Sunitinib was relatively well tolerated. Almost all patients experienced one or more treatment-related adverse event. Discussion: Based on our limited experience, we concluded that sunitinib is reasonable treatment option for patients with imatinibresistant GIST.
Description
Keywords
Cancer, Sunitinib, Gastrointestinal stromal tumors, General & internal medicine